APP
APP
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
57 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
APP has an insider buy conviction of 50%, compared to the Unknown sector buy average of 50%.
Multiple Insiders
S - Sale Insiders
$0 total
Over the last 90 days, corporate insiders at APP (APP) engaged in a total of 57 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for APP shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (S - Sale Insiders), who traded 123.6K shares valued at $0 on Jul 6, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering APP and the Unknown sector.
Legal vs. Illegal Insider Trading: Setting the Record Straight
The line between legal and illegal insider trading is narrower than most investors realize. This explainer covers the material non-public information standard, the Misappropriation Theory, and how regulators reconstruct trading chronologies.
Tracking Insider Activity in Biotech: High Stakes and Hidden Signals
Biotech insiders possess unique asymmetric information, clinical results, FDA feedback, partnership negotiations. This guide explains how to track Form 4 activity at pre-commercial biotechs, what position sizes matter, and how to avoid false signals near data events.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Why Tech Executives Voluntarily Accept Stock Over Cash Compensation
Many tech executives voluntarily elect equity compensation over cash, and these elections appear as Form 4 events. This report explains why this practice is widespread in tech, how to interpret voluntary equity elections on Form 4, and what they signal about executive sentiment.
Biotech Insider Buying: Analyzing Clinical Trial Catalysts
Biotech insiders walk a legal tightrope near trial readouts. This report identifies statistically significant buying clusters at small-cap biotechs 30-90 days before Phase 2 and Phase 3 data announcements.
Insider Buying vs. Stock Buybacks: Which Signal Should You Follow?
Corporate buybacks and insider purchases are both bullish signals — but they differ fundamentally in what they mean, how reliable they are, and how you should incorporate them into your investment analysis. This guide breaks down the mechanics, academic research, and practical applications of both signals.
FAQs About APP Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for APP.